Physician profile
Shan Guo
NPI 1144405945
$30,810.64
in general payments reported to CMS, 2019-2025
70 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $1,713 · 2021: $3,686 · 2022: $1,359 · 2023: $7,470 · 2024: $5,349 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $7,425 · Education: $318 · Travel and Lodging: $247 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,322.50 |
| Food and Beverage | $7,424.70 |
| Education | $317.96 |
| Travel and Lodging | $246.65 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,752.79 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Karyopharm Therapeutics INC. | $5,608.89 | 2020-2025 | Xpovio |
| Novartis Pharmaceuticals Corporation | $2,873.89 | 2019-2025 | |
| Sirtex Medical INC | $2,790.81 | 2023-2025 | Sir-Spheres Microspheres |
| G1 Therapeutics, INC. | $1,525.64 | 2021-2022 | |
| Gilead Sciences, INC. | $1,285.87 | 2021-2025 | Trodelvy |
| Immunomedics, INC. | $1,000.00 | 2020 | |
| Pfizer INC. | $824.18 | 2019-2025 | |
| Daiichi Sankyo INC. | $740.72 | 2020-2025 | Enhertu, Datroway, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $663.08 | 2019-2025 | Opdivo, Opdualag |
| Eisai INC. | $530.32 | 2019-2025 | |
| Abbvie INC. | $504.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $456.14 | 2020-2025 | Ojjaara, Blenrep, Jemperli |
| Merck Sharp & Dohme LLC | $445.97 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $402.51 | 2020-2025 | Reblozyl, Pomalyst |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shan Guo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.